Sunday, 22 September 2013

23 September, 2013

Beware – Facebook can cause short-term memory loss!

Are you always logged in? Take a break. A new study warns that too much time browsing social media could lead to short-term memory loss. Contrary to common wisdom, an idle brain is in fact doing important work – and in the age of constant information overload, it’s a good idea to go offline on a regular basis, according to a researcher from Stockholm’s KTH Royal Institute of Technology.
Erik Fransen, whose research focuses on short-term memory and ways to treat diseased neurons, said that a brain exposed to a typical session of social media browsing can easily become hobbled by information overload.  The result is that less information gets filed away in your memory.
The problem begins in a system of the brain commonly known as the working memory, or what most people know as short-term memory. That’s the system of the brain that we need when we communicate, Fransen said.  ‘Working memory enables us to filter out information and find what we need in the communication. It enables us to work online and store what we find online, but it’s also a limited resource,’ he said.
‘At any given time, the working memory can carry up to three or four items. When we attempt to stuff more information in the working memory, our capacity for processing information begins to fail.
‘When you are on Facebook, you are making it harder to keep the things that are ‘online’ in your brain that you need.  ‘In fact, when you try to process sensory information like speech or video, you are going to need partly the same system of working memory, so you are reducing your own working memory capacity.
‘And when you try to store many things in your working memory, you get less good at processing information,’ he said.  You’re also robbing the brain of time it needs to do some necessary housekeeping. The brain is designed for both activity and relaxation, Fransen said.
‘The brain is made to go into a less active state, which we might think is wasteful; but probably memory consolidation, and transferring information into memory takes place in this state. Theories of how memory works explain why these two different states are needed.  ‘When we max out our active states with technology equipment, just because we can, we remove from the brain part of the processing, and it can’t work,’ Fransen said.
23.09.2013



Now – a nano-medicine for blood cancer!

Coinciding with the 60th birthday of Mata Amritanandamayi, the Kochi-based Amrita Centre for Nanosciences and Molecular Medicine has developed a nano-medicine for drug-resistant blood cancer.
This is expected to dramatically improve the treatment of drug-resistant chronic myelogenous leukemia (CML), when used in combination with Imatinib, the standard drug for the disease.
In another significant invention, the 2006-founded Amrita Centre has devised a mechanism that can effectively prevent recurrence of glioma or brain tumour.
This deadly disease affects about four out of every 100,000 people in India. The life expectancy of high-grade glioma patients is about one to two years.
The two projects will be formally unveiled Sep 26 at Amritavarsham60, the 60th birthday celebrations of the hugging saint or Amma as she is popularly referred to by her devotees.
CML annually affects approximately two out of every 100,000 Indians. Almost 40 per cent of these cases are resistant to Imatinib. For such patients, treatment options are extremely limited.
‘What we have done at Amrita is to take a particular ‘small-molecule inhibitor’ class of anti-cancer drug, currently available in the market and encapsulate it into a protein nano-capsule,’ said Shantikumar Nair, the centre’s director.
‘This allows the drug to be absorbed directly into the cancer cells circulating in the patient’s bloodstream. This has a marked increase on its efficacy in killing cancer cells. Further, the circulation lifetime of the drug in the blood is increased, which also enhances its efficacy,’ he added.
The nano-encapsulated version of the drug has shown itself to be non-toxic in healthy mice in tests conducted by his department, and it has similarly demonstrated itself to be effective in tests involving blood samples of people with Imatinib-resistant CML.
Manzoor Koyakutty, professor at the Centre, says the next step is to evaluate its efficacy in fighting CML in mice. ‘If it continues to remain non-toxic and effective, we can move on to clinical trials,’ added the expert and drug co-inventor. 
23.09.2013







Coming together is a beginning. Keeping together is progress.Working together is success.
Henry Ford


No comments:

Post a Comment